One of Europe's leading research-intensive universities
@clarivate.com
@clarivate.com
👏 @novaucd.bsky.social
👏 @novaucd.bsky.social
📸 by Tom Evans
📸 by Tom Evans
👏 @nuimerrionsq.bsky.social
👏 @nuimerrionsq.bsky.social
@businesspost.bsky.social @ucdmedicine.bsky.social
@businesspost.bsky.social @ucdmedicine.bsky.social
#UniversityCollegeDublin #Autumn #2025
#UniversityCollegeDublin #Autumn #2025
Discover everything you need to know about your chosen courses, explore our vibrant campus, and meet the UCD community.
Discover everything you need to know about your chosen courses, explore our vibrant campus, and meet the UCD community.
@ucdengarch.bsky.social
@ucdengarch.bsky.social
🧵 @naokody.bsky.social
🧵 @naokody.bsky.social
#ucd #UCDLife #UniversityCollegeDublin #autumn #ireland
#ucd #UCDLife #UniversityCollegeDublin #autumn #ireland
👏 @susigeiger.bsky.social
👏 @susigeiger.bsky.social
Ar dheis Dé go raibh a hanam dílis.
Ar dheis Dé go raibh a hanam dílis.
@aidanosullivan.bsky.social
@aidanosullivan.bsky.social
NovaUCD spin-out company LirOptic has won the Audience Choice Award at the final of the 2025 Luminate NY accelerator programme in New York, taking home a $10,000 (€8.6k) prize.
NovaUCD spin-out company LirOptic has won the Audience Choice Award at the final of the 2025 Luminate NY accelerator programme in New York, taking home a $10,000 (€8.6k) prize.
🔗 Read the full story: www.ucd.ie/newsandopini...
🔗 Read the full story: www.ucd.ie/newsandopini...
A quantum computing project led by Equal1, a spin-out company of NovaUCD, has secured €13.7 million in funding from the Disruptive Technologies Innovation Fund (DTIF).
A quantum computing project led by Equal1, a spin-out company of NovaUCD, has secured €13.7 million in funding from the Disruptive Technologies Innovation Fund (DTIF).
#UCD #UCDDublin #UCDLife #AutumnInIreland #IrishAutumn #DublinDays #Belfield #UCDCampus #OctoberLight #OrangeDay
The investment came from Research Ireland and APC Ltd, an Irish biopharmaceutical process development and manufacturing company.
The investment came from Research Ireland and APC Ltd, an Irish biopharmaceutical process development and manufacturing company.